Ambrx Biopharma Current Ratio 2020-2021 | AMAM

Ambrx Biopharma current ratio from 2020 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Ambrx Biopharma Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.17B $0.02B 9.90
2020-12-31 $0.09B $0.01B 7.02
2019-12-31 $0.02B $0.02B 1.22
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.322B $0.014B
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $126.808B 8.01
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $6.887B 0.00
Arcus Biosciences (RCUS) United States $3.210B 0.00
Emergent Biosolutions (EBS) United States $2.270B 8.16
Myovant Sciences (MYOV) United Kingdom $1.508B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.469B 0.00
Zymeworks (ZYME) Canada $0.850B 0.00
SQZ Biotechnologies (SQZ) United States $0.326B 0.00
Enzo Biochem (ENZ) United States $0.170B 16.71